Pascal Touchon - 10 Jun 2025 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: Director
Issuer ticker: ATRA
Reported as of: 10 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2025, 20:39:15 UTC
Prior SEC filing: 20 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ John Chao, Attorney-in-Fact for Pascal Touchon

Key filing fact

Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 12 Jun 2025.

Key facts

This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2025, 20:39.

Change

Previous filing in this sequence was filed on 20 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780060 Primary reporting owner

Touchon Pascal

Relationship: Director
Address: C/O ATARA BIOTHERAPEUTICS, INC., 1280 RANCHO CONEJO BOULEVARD, THOUSAND OAKS
Signature: /s/ John Chao, Attorney-in-Fact for Pascal Touchon
Signature date: 12 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Award

Transaction value: $0
Shares: +7,828
Change %: +11%
Price: $0.000000
Shares after: 77,955
Date: 10 Jun 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.